News >

PARP Inhibition: A Necessity of Treatment in Recurrent Ovarian Cancer

Caroline Seymour
Published: Wednesday, Aug 28, 2019

Debra Richardson, MD

Debra Richardson, MD

PARP inhibitors have become an integral treatment strategy for women with BRCA-mutated high-grade serous ovarian and endometrioid cancer, as both a later-line therapy and as a maintenance therapy following platinum-based chemotherapy, said Debra Richardson, MD, FACOG, FACS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication